Cantor Fitzgerald reiterates Overweight on Ultragenyx, $39 target
Cantor Fitzgerald maintained an Overweight rating on Ultragenyx Pharmaceutical and kept a $39.00 price target, implying 169.0% upside versus the Sep 17 close of $14.50.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.